{"id":453,"date":"2026-08-27T10:31:11","date_gmt":"2026-08-27T10:31:11","guid":{"rendered":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"modified":"2026-08-28T07:31:46","modified_gmt":"2026-08-28T07:31:46","slug":"tesamorelin-hiv-lipodystrophy-randomized-trials","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/es\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","title":{"rendered":"Lipodistrofia asociada a Tesamorelin y HIV: lo que midieron los ensayos aleatorios"},"content":{"rendered":"
Tesamorelin es un an\u00e1logo del factor liberador de la hormona del crecimiento con una base de evidencia cl\u00ednica definida en adultos con lipodistrofia asociada a HIV. Esa poblaci\u00f3n espec\u00edfica y el contexto de los criterios de valoraci\u00f3n son esenciales: la evidencia no debe generalizarse a una afirmaci\u00f3n amplia del consumidor sobre la p\u00e9rdida de peso.<\/p>
Conclusiones clave<\/h2>
Los estudios fundamentales midieron el tejido adiposo visceral en adultos con acumulaci\u00f3n de grasa abdominal asociada a HIV.<\/li>
La etiqueta FDA indica que el producto aprobado no est\u00e1 indicado para el control de la p\u00e9rdida de peso.<\/li>
La evidencia de producto aprobado no establece equivalencia para un material de investigaci\u00f3n suministrado de forma independiente.<\/li><\/ul><\/div><\/div>Ilustraci\u00f3n editorial original de una revisi\u00f3n de im\u00e1genes abdominales en un estudio de lipodistrofia asociada a HIV; no se representa ning\u00fan paciente ni producto.<\/figcaption><\/figure>
El contexto biol\u00f3gico y cl\u00ednico.<\/h2>
Tesamorelin es un an\u00e1logo del factor liberador de hormona del crecimiento. En el entorno estudiado, estimula la liberaci\u00f3n de la hormona del crecimiento hipofisaria y aumenta la se\u00f1alizaci\u00f3n de IGF-1. Los ensayos relevantes incluyeron a personas que viv\u00edan con HIV y que ten\u00edan exceso de grasa abdominal en el contexto de la terapia antirretroviral.<\/p>
Ese contexto es importante porque la lipodistrofia asociada a HIV no es intercambiable con la obesidad general, y el tejido adiposo visceral medido mediante im\u00e1genes no es el mismo criterio de valoraci\u00f3n que la p\u00e9rdida de peso general.<\/p>
Lo que encontr\u00f3 el estudio aleatorizado de un mes de duraci\u00f3n 12<\/h2>
Un estudio aleatorizado y controlado con placebo con participantes de 404 utiliz\u00f3 tejido adiposo visceral como criterio de valoraci\u00f3n principal. Los investigadores informaron una reducci\u00f3n de la grasa visceral durante la fase aleatoria inicial y persistencia entre los participantes que continuaron el tratamiento. Las mejoras se perdieron despu\u00e9s de cambiar de tesamorelin a placebo, lo que ayuda a aclarar la dependencia del efecto observado de la exposici\u00f3n continua en ese protocolo.<\/p>
Un estudio aleatorio m\u00e1s peque\u00f1o tambi\u00e9n evalu\u00f3 la grasa del h\u00edgado y el tejido adiposo visceral. Sus resultados fueron exploratorios en cuanto a resultados relacionados con el h\u00edgado y no deben convertirse en una indicaci\u00f3n aprobada de enfermedad hep\u00e1tica.<\/p>
Poblaci\u00f3n<\/strong>Adultos con HIV y exceso de grasa abdominal<\/span><\/div>
Medici\u00f3n primaria<\/strong>Tejido adiposo visceral mediante im\u00e1genes.<\/span><\/div>
Limitaci\u00f3n importante<\/strong>No es una poblaci\u00f3n o indicaci\u00f3n general para el control de peso.<\/span><\/div><\/div><\/div>
L\u00edmites de etiquetas que pertenecen a cada resumen<\/h2>
La etiqueta 2025 EGRIFTA WR identifica una formulaci\u00f3n e indicaci\u00f3n aprobadas espec\u00edficas. Tambi\u00e9n se\u00f1ala que no se ha establecido la seguridad cardiovascular a largo plazo y que el producto no est\u00e1 indicado para el control de la p\u00e9rdida de peso. Esas limitaciones son parte de la evidencia, no letra peque\u00f1a opcional.<\/p>","protected":false},"excerpt":{"rendered":"
Una revisi\u00f3n basada en evidencia de los ensayos de tesamorelina en adultos con acumulaci\u00f3n de grasa abdominal asociada a HIV, que incluye criterios de valoraci\u00f3n, l\u00edmites y contexto etiquetado con FDA.<\/p>","protected":false},"author":1,"featured_media":623,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pim_family_ids":"367","pim_article_type":"Clinical evidence review","pim_evidence_level":"Randomized controlled human trials and FDA labeling","pim_reviewer":"NHD evidence editorial workflow","pim_reviewed_date":"2026-08-27","pim_editorial_note":"Source-checked against the linked primary or authoritative records on 2026-08-27. This is an evidence summary, not independent peer review, medical advice or validation of a catalog lot.","pim_review_status":"reviewed","pim_review_reason":"At least two linked primary or authoritative records and an explicit evidence boundary are present.","pim_creation_method":"The editorial workflow starts with linked peer-reviewed papers, trial registries or regulatory records; extracts the population or model, endpoints, numerical results and limitations; and separates the studied intervention from catalog material. AI-assisted drafting was used to structure the first version. Claims, figures, evidence labels and limitations were checked against the linked records in the site editorial workflow. This is not independent peer review.","pim_sources":"[{\"title\":\"Randomized tesamorelin trial with 12-month extension\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/20101189\/\",\"note\":\"Primary human trial; PMID 20101189.\"},{\"title\":\"Randomized trial of visceral and liver fat outcomes\",\"url\":\"https:\/\/pubmed.ncbi.nlm.nih.gov\/25038357\/\",\"note\":\"Exploratory liver-fat evidence; PMID 25038357.\"},{\"title\":\"FDA EGRIFTA WR prescribing information\",\"url\":\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/022505s020lbl.pdf\",\"note\":\"Approved-product indication and limitations.\"}]","footnotes":""},"categories":[18],"tags":[],"class_list":["post-453","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-evidence-reviews"],"yoast_head":"\n
Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured - NHD<\/title>\n<meta name=\"description\" content=\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/es\/tesamorelin-hiv-lipodystrophy-randomized-trials\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\" \/>\n<meta property=\"og:description\" content=\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/es\/tesamorelin-hiv-lipodystrophy-randomized-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-27T10:31:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-28T07:31:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"960\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"NHD Technical Team\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"NHD Technical Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"},\"author\":{\"name\":\"NHD Technical Team\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\"},\"headline\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"},\"wordCount\":344,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"articleSection\":[\"Evidence Reviews\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\",\"name\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured - NHD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"datePublished\":\"2026-08-27T10:31:11+00:00\",\"dateModified\":\"2026-08-28T07:31:46+00:00\",\"description\":\"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/generated-news\\\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp\",\"width\":1536,\"height\":960,\"caption\":\"Article-specific editorial image.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/tesamorelin-hiv-lipodystrophy-randomized-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/person\\\/0ffb0dec7fda0f720073fc468fac6fc1\",\"name\":\"NHD Technical Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g\",\"caption\":\"NHD Technical Team\"},\"description\":\"NHD Technical Team maintains research-use catalog documentation and evidence summaries. Reviewed articles link to peer-reviewed papers, trial registries and regulatory records, retain null findings and study limitations, and distinguish published interventions from catalog materials. AI-assisted drafting may be used for structure; source links and evidence boundaries remain visible. This work is not independent peer review or medical advice.\",\"sameAs\":[\"https:\\\/\\\/nhdbio.com\"],\"url\":\"https:\\\/\\\/nhdbio.com\\\/es\\\/author\\\/qianmiao-technical-team\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lipodistrofia asociada a Tesamorelin y HIV: lo que midieron los ensayos aleatorios - NHD","description":"Una revisi\u00f3n basada en evidencia de los ensayos de tesamorelina en adultos con acumulaci\u00f3n de grasa abdominal asociada a HIV, que incluye criterios de valoraci\u00f3n, l\u00edmites y contexto etiquetado con FDA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/es\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","og_locale":"es_ES","og_type":"article","og_title":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured","og_description":"An evidence-led review of tesamorelin trials in adults with HIV-associated abdominal fat accumulation, including endpoints, limits and FDA-labeled context.","og_url":"https:\/\/nhdbio.com\/es\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","og_site_name":"NHD","article_published_time":"2026-08-27T10:31:11+00:00","article_modified_time":"2026-08-28T07:31:46+00:00","og_image":[{"width":1536,"height":960,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","type":"image\/webp"}],"author":"NHD Technical Team","twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Escrito por":"NHD Technical Team","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#article","isPartOf":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"author":{"name":"NHD Technical Team","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1"},"headline":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","mainEntityOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"},"wordCount":344,"commentCount":0,"publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","articleSection":["Evidence Reviews"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","url":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/","name":"Lipodistrofia asociada a Tesamorelin y HIV: lo que midieron los ensayos aleatorios - NHD","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","datePublished":"2026-08-27T10:31:11+00:00","dateModified":"2026-08-28T07:31:46+00:00","description":"Una revisi\u00f3n basada en evidencia de los ensayos de tesamorelina en adultos con acumulaci\u00f3n de grasa abdominal asociada a HIV, que incluye criterios de valoraci\u00f3n, l\u00edmites y contexto etiquetado con FDA.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/generated-news\/tesamorelin-hiv-lipodystrophy-randomized-trials-featured-v2.webp","width":1536,"height":960,"caption":"Article-specific editorial image."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/tesamorelin-hiv-lipodystrophy-randomized-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"Tesamorelin and HIV-Associated Lipodystrophy: What Randomized Trials Measured"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Materias primas pept\u00eddicas y s\u00edntesis personalizada","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/nhdbio.com\/#\/schema\/person\/0ffb0dec7fda0f720073fc468fac6fc1","name":"Equipo t\u00e9cnico de NHD","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8445618b3e2834fa0c7ae1a03a371ed002e9bf8d2cc1cd989dc4a71bb2b66110?s=96&d=mm&r=g","caption":"NHD Technical Team"},"description":"El equipo t\u00e9cnico de NHD mantiene documentaci\u00f3n del cat\u00e1logo de uso de investigaci\u00f3n y res\u00famenes de evidencia. Los art\u00edculos revisados \u200b\u200benlazan con art\u00edculos revisados \u200b\u200bpor pares, registros de ensayos y registros regulatorios, conservan hallazgos nulos y limitaciones de estudios, y distinguen las intervenciones publicadas de los materiales del cat\u00e1logo. Se puede utilizar dibujo asistido por AI para la estructura; los enlaces de fuentes y los l\u00edmites de las pruebas permanecen visibles. Este trabajo no es una revisi\u00f3n por pares independiente ni un consejo m\u00e9dico.","sameAs":["https:\/\/nhdbio.com"],"url":"https:\/\/nhdbio.com\/es\/author\/qianmiao-technical-team\/"}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/comments?post=453"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/453\/revisions"}],"predecessor-version":[{"id":518,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/posts\/453\/revisions\/518"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media\/623"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/media?parent=453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/categories?post=453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhdbio.com\/es\/wp-json\/wp\/v2\/tags?post=453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"Investigador](\"http:\/\/nhdbio.com\/wp-content\/uploads\/2026\/08\/tesamorelin-hiv-visceral-fat-research.png\")